Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 4Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma 1

Interventions

pembrolizumab 224Cyclophosphamide 192Radiotherapy 183Nivolumab 180Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 104Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 91Ipilimumab 81Doxorubicin 79Lenalidomide 76durvalumab 75Rituximab 75atezolizumab 72Radiation 72venetoclax 69fludarabine 68Standard of Care 68Gemcitabine 68Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × brexucabtagene autoleucel × Clear all
NCT05495464 2026-05-20

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT03642626 2026-01-23

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
150 enrolled 23 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡